 |
 |
Date Announced: 11 Mar 2015
PARIS, March 11, 2015 /PRNewswire/ -- Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced several developments showing adoption and expanded use of the Cellvizio technology platform in multiple diagnostic applications in Japan.
Cellvizio received MHLW regulatory approval in Japan in April 2014 and is now installed in ten leading hospitals throughout the country including the National Cancer Center Hospital in Tokyo. In response to growing interest among clinicians and researchers, the Japanese Gastroenterological Endoscopy Society (JGES) also established a special interest group on confocal laser endomicroscopy (CLE) to advance a range of key initiatives and learning opportunities.
On March 7th, Dr. Ken Ohata, Director of Endoscopy at NTT Medical Center Tokyo, performed the first-ever live procedure involving the use of Cellvizio in Japan at the 14th Yokohama International Endoscopy Conference. Prof. Shinei Kudo, Chairman of Digestive Disease Center, Showa University Northern Yokohama Hospital, cofounder of the Magnifying Endoscopy Society in Japan and Course Director of the conference, commented, "We had a very powerful demonstration of endoscopic microscopy technologies at the 14th Yokohama Live. These technologies are an increasingly important part of the future of endoscopy and I fully support their continued development in Japan."
In addition, more than 25 leading physicians from Japan will take part in the upcoming International Conference of Cellvizio Users (ICCU) to be held in Lisbon on April 10th. Dr. Yutaka Saito, Chief of Endoscopy at National Cancer Center Hospital, is the incoming chairman of the ICCU meeting.
"Diagnosis and treatment of digestive cancers remain a critical health issue in Japan, and the ability to characterize these cancers faster and with improved specificity could have a significant impact on patient care and outcomes," said Dr. Saito. "We are very proud to be leading the clinical development of confocal laser endomicroscopy in Japan where the attention to analysis at the microscopic level has for many years been a primary focus and goal."
In addition to the Yokohama meeting, data and case studies related to use of Cellvizio will be presented at 13 different medical congresses in Japan in 2015.
"Japanese physicians have been leading the development of endoscopy for decades. We are very proud to see that Cellvizio is already available at many of the top research and treatment centers in Japan and that it is receiving strong support from many of the leaders in the endoscopy community," said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies. "We look forward to working with even more leading physicians throughout Japan to bring the clinical value of Cellvizio to more hospitals and patients, and we are confident that more important applications of our technology will be developed in this significant market."
Optical biopsy with Cellvizio enables the visualization of tissues at the cellular level during an endoscopic examination to determine the presence of diseases and conditions such as cancer. The procedure combines CLE with standard endoscopy and produces images with microscopic precision that can provide physicians with real-time information to support faster and more accurate diagnosis.
Source: Mauna Kea Technologies
E-mail: via web site
Web Site: www.maunakeatech.com
| © 2024 SPIE Europe |
|
